Pain blocker
The experimental drug filgotinib blocks a set of enzymes that cause inflammation in rheumatoid arthritis patients who haven’t benefitted from other treatments, a study shows.
The experimental drug filgotinib provides relief from rheumatoid arthritis by blocking a set of enzymes that cause inflammation, a Stanford-led trial shows.
About 75 million people suffer joint pain, stiffness, inflammation and deterioration from rheumatoid arthritis. But three-quarters of patients surveyed reported being dissatisfied with treatment.
“For patients who haven’t done well on other therapies, these findings are cause for optimism, enthusiasm and hope,” said author Mark Genovese, MD, professor of immunology and rheumatology and the lead author of a paper describing the trial published July 23 in JAMA.